The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.

Last week, readers were most interested in a story about whether digital pathology is approaching a breakout moment in its adoption curve.

Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.

The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.

NEW YORK – German digital pathology company Mindpeak announced Monday that it has raised $15.3 million in a Series A financing round.

The deal comes on the heels of a similar arrangement Nanostics struck with Protean BioDiagnostics for the US market.

The University of Maryland spinout said it plans to launch a point-of-care urinary tract infection test by 2025, followed by three more tests by 2028.

Leo Li has resigned as CFO of Burning Rock Biotech and from its board, effective Sept. 27. The Guangzhou, China-based developer of next-generation sequencing-based cancer tests said Li's resignation ...

According to the government, Rashid Naqvi, a Houston-area resident, fraudulently sought $4.6 million from Medicare for COVID-19 test kits and obtained $2.0 million.